Fycompa perampanel regulatory update

Germany's Federal Joint Committee (G-BA) granted a request from Eisai for a new benefit assessment for Fycompa perampanel for epilepsy. Eisai now has 3 months to submit a new dossier for the AMPA-type glutamate receptor antagonist. G-BA said it granted the request because of an amendment to guidelines implementing drug pricing law AMNOG that eliminated the requirement for G-BA to conduct benefit assessments of new therapies vs. the lowest-cost alternative. ...